Research Progress on Desquamative interstitial pneumonitis

Corresponding author: liuyao, 152101920@qq.com

DOI: 10.12201/bmr.202506.00026

•  

  Abstract: Desquamative interstitial pneumonitis (DIP) is an idiopathic interstitial pneumonia whose main pathological feature is the extensive infiltration of macrophages in the alveoli followed by interstitial inflammation and fibrosis. The etiology of DIP is unknown, but there is a strong association with smoking. Patients often present with progressively worsening cough and shortness of breath, and high-resolution chest CT is the imaging modality of choice. Surgical lung biopsy remains the gold standard for diagnosing DIP, although transbronchial frozen biopsy is being investigated as an alternative. The standard treatment for DIP is smoking cessation and steroid therapy. The prognosis for patients is generally favorable, with most improving after quitting smoking and receiving corticosteroid therapy.

  Key words: Interstitial Pneumonias; Diffuse Parenchymal Lung Disease; Pulmonary Fibrosis; Respiratory System Diseases

  Submit time: 11 June 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• LIU Ruyang, ZHANG Guopeng, SUN Hongwei, FANG Zhensheng. Research progress of IL-37 in respiratory diseases. 2025. doi: 10.12201/bmr.202501.00038

  Guan Wei, Xue Xiaoming. Progress of Trditional Chinese Medicine Targeting Alveolar Epithelial Cell Senescence in the Treatment of Pulmonary Fibrosis. 2025. doi: 10.12201/bmr.202506.00012

  WangJing. Research progress of Xiangsha Liujunzi Tang in digestive system diseases. 2025. doi: 10.12201/bmr.202503.00015

  HANG Yu-jie, CHEN Kun, LIU Qian-yu, ZHANG Yu-bin, XU Liang, ZHANG Li-xue, BAI Jing-ya▲. Research progress of biomarkers for renal fibrosis. 2024. doi: 10.12201/bmr.202411.00072

  zhaofenqin. . 2025. doi: 10.12201/bmr.202501.00040

  Lin ZhiFeng, ZHANG ChuJian, LIU Dong, Kong YiJing. To explore the optimal intervention time of 1.25 (OH) 2D3 to protect renal interstitialfibrosis based on NF-κB inflammatory pathway. 2025. doi: 10.12201/bmr.202504.00063

  LIANG Ningjuan, WU Ting, YU Dandan, JIANG Xiaohan, TENG Jingjing. Effective exploration of the toxicity and molecular mechanisms of plasticisers in pulmonary fibrosis by network toxicology and molecular docking strategies: an example of butylbenzyl phthalate. 2025. doi: 10.12201/bmr.202504.00004

  LI Shumin. Progress in the study of secretory frizzled-associated protein 1 and lung diseases. 2024. doi: 10.12201/bmr.202408.00013

  YANG Ziliang, ZHAO Zixiong, ZHANG Yewu, MA Jiaqi. A Research on the Construction of a Case Epidemiological Portrait Labeling System for Respiratory Infectious Diseases. 2022. doi: 10.12201/bmr.202112.00010

  Zhenghaijuan, NiuXiaohan. Research Progress of CCR and metabolic syndrome and its related diseases. 2025. doi: 10.12201/bmr.202501.00048

• ID	Submit time	Number	Download
  1	2025-05-17	bmr.202506.00026V1	Download

• Public  Anonymous  To author only Submit Comments